摘要
目的观察结直肠癌组织中趋化因子CXCR5及其配体CXCL13以及MMP-12、MMP-13的表达,探讨其与临床病理特征、预后的关系。方法应用免疫组织化学SP法检测236例结直肠癌及其切缘正常肠黏膜组织以及62例结直肠腺瘤组织中CXCR5、CXCL13、MMP-12和MMP-13蛋白表达。结果 (1)CXCR5、CXCL13、MMP-12、MMP-13在结直肠癌组织中的表达率为43.6%、41.5%、83.5%和80.5%均高于在切缘正常肠黏膜组织中的表达率(4.2%、5.5%、11.9%和13.1%)及在结直肠腺瘤组织中的表达率(24.2%、17.7%、69.4%和64.5%)(P均<0.05)。(2)CXCR5、CXCL13、MMP-12、MMP-13蛋白表达与淋巴结转移、远处转移、肿瘤分期及复发呈正相关(P<0.05)。CXCL13蛋白表达与组织分化程度呈正相关(P<0.05)。(3)CXCR5与CXCL13蛋白表达呈正相关(P<0.05)。CXCR5、CXCL13蛋白表达分别与MMP-12和MMP-13呈正相关(P<0.05)。结论 CXCR5、CXCL13、MMP-12、MMP-13的表达促进结直肠癌的发生、发展以及转移、复发,可作为预测结直肠癌转移和复发的有价值指标。
Objective To investigate the expression of CXCR5, CXCL13, MMP-12 and MMP-13, and to explore their relationship with clinicopathologic features and prognosis of colorectal carcinoma. Methods The immunohistochemistry staining method was used to detect the expression of CXCR5, CXCL13, MMP-12 and MMP-13 protein in 236 paired specimens of colorectal cancer and normal tissues and 62 cases of colorectal adenoma. Results The positive rates of CXCR5, CXCL13, MMP-12 and MMP-13 were 43.6%, 41.5%, 83.5% and 80.5% in colorectal carcinoma tissues, respectively, which were much higher than those in incisal edge normal intestinal mucosa tissues(4.2%, 5.5%, 11.9% and 13.1%) and those in colorectal adenomas tissues(24.2%, 17.7%, 69.4% and 64.5%)(P<0.05). The expression of CXCR5, CXCL13, MMP-12 and MMP-13 were positively correlated with lymph node metastasis, distant metastasis, TNM stage and relapse(P <0.05). Additionally, CXCL13 positive staining was correlated with poor differentiation(P<0.05). CXCR5 expression was significantly correlated with CXCL13 expression(P<0.05). The expression of CXCR5 and CXCL13 were positively correlated with MMP-12 and MMP-13, respectively(P<0.05). Conclusion The expression of CXCR5,CXCL13,MMP-12 and MMP-13 may play a crucial role in the carcinogenesis, development, metastasis and relapse of colorectal cancer. They could be used as prognostic markers of colorectal cancer in clinical practice.
引文
[1]Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
[2]Markowitz SD,Dawson DM,Willis J,et al.Focus on colon cancer[J].Cancer Cell,2002,1(3):233-6.
[3]Labianca R,Nordlinger B,Beretta GD,et al.Primary colon cancer:ESMO Clinical Practice Guidelines for diagnosis,adjuvant treatment and follow-up[J].Ann Oncol,2010,21 Suppl 5:v70-7.
[4]Franciszkiewicz K,Boissonnas A,Boutet M,et al.Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response[J].Cancer Res,2012,72(24):6325-32.
[5]Kataoka H,Tanaka H,Nagaike K,et al.Role of cancer cell-stroma interaction in invasive growth of cancer cells[J].Hum Cell,2003,16(1):1-14.
[6]Müller G,Hopken UE,Lipp M.The impact of CCR7 and CXCR5on lymphoid organ development and systemic immunity[J].Immunol Rev,2003,195:117-35.
[7]Bürkle A,Niedermeier M,Schmitt-Groff A,et al.Overexpression of the CXCR5 chemokine receptor,and its ligand,CXCL13 in B-cell chronic lymphocytic leukemia[J].Blood,2007,110(9):3316-25.
[8]Meijer J,Zeelenberg IS,Sipos B,et al.The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver[J].Cancer Res,2006,66(19):9576-82.
[9]Freije JM,Díez-Itza I,Balbín M,et al.Molecular cloning and expression of collagenase-3,anovel human matrix metalloproteinase produced by breast carcinomas[J].J Biol Chem,1994,269(24):16766-73.
[10]Mori M,Barnard GF,Mimori K,et al.Overpression of matri x metalloproteinase-7 m RNA in human colon carcinomas[J].Cancer,1995,75(6 Suppl):1516-9.
[11]VAN Nguyen S,Skarstedt M,Lfgren S,et al.Gene polymorphism of matrix metalloproteinase-12 and-13 and association with colorectal cancer in Swedish patients[J].Anticancer Res,2013,33(8):3247-50.
[12]Razis E,Kalogeras KT,Kotoula V,et al.Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression[J].Clin Breast Cancer,2012,12(3):183-93.
[13]Rath T,Stockle J,Roderfeld M,et al.Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration[J].Oncol Lett,2011,2(3):483-8.